This application is a continuation of Sack, U.S. Patent Appl. Publ. No. 2019/0151113, published May 23, 2019, and entitled “Implant with Improved Flow Characteristics,” the entire disclosure of which is incorporated herein by reference.
The embodiments are generally directed to implants for supporting bone growth in a patient.
A variety of different implants are used in the body. Implants used in the body to stabilize an area and promote bone ingrowth provide both stability (i.e., minimal deformation under pressure over time) and space for bone ingrowth.
Spinal fusion, also known as spondylodesis or spondylosyndesis, is a surgical treatment method used for the treatment of various morbidities such as degenerative disc disease, spondylolisthesis (slippage of a vertebra), spinal stenosis, scoliosis, fracture, infection, or tumor. The aim of the spinal fusion procedure is to reduce instability and thus pain.
In preparation for the spinal fusion, most of the intervertebral disc is removed. An implant, the spinal fusion cage, may be placed between the vertebrae to maintain spine alignment and disc height. The fusion, i.e., bone bridge, occurs between the endplates of the vertebrae.
Cage-style vertebral implants may be filled with bone graft material for implantation. Bone graft material can be a relatively viscous and even chunky material, and thus, can be difficult to introduce into the cage. In addition, different types of bone can have different structural properties. For example, cortical bone, also called compact bone or lamellar bone, forms the cortex, or outer shell, of most bones, including vertebrae. It is much denser than cancellous bone, as well as harder, stronger, and stiffer. Cortical bone contributes about 80% of the weight of a human skeleton. Cancellous bone, also called trabecular bone or spongy bone, has a higher surface area but is less dense than cortical bone, as well as softer, weaker, and less stiff. Cancellous bone typically occurs at the ends of long bones, proximal to joints and within the interior of vertebrae.
Because the same implant may support both cortical bone and cancellous bone, implants having consistent structural configuration and properties at bone confronting surfaces, may produce differing bone ingrowth results in different parts of the bone. For example, the cortical bone portion of vertebrae may respond differently to a spinal fusion implant than the cancellous bone core of the vertebrae.
It would be desirable to address these issues in intervertebral implants.
The present disclosure is directed to intervertebral implants that include provisions to improve flow of bone graft material into the inner volume of the implant as well as structural configurations that vary across bone contacting surfaces of the implant. In particular, the disclosed implant may include a central portion that has a reduced density of trusses that form the cage. This may facilitate introduction of the bone graft material and also focus the structural support areas to the peripheral portion, which corresponds with the cortical bone area of vertebrae. In addition, the disclosed implant may include struts having particular orientations and arrangements that promote flow of bone graft material. For example, the disclosed implant may include struts having non-circular cross-sectional shapes, which may be oriented to facilitate and direct flow of bone graft material through the inner volume of the implant.
In one aspect, the present disclosure is directed to an intervertebral implant including a body formed as an open truss structure. The body may have a generally annular shape with a superior surface, an inferior surface, and a perimeter surface, the perimeter surface extending around an outer periphery of the body. The body has a central portion and a peripheral portion, the peripheral portion extending inward from the perimeter surface toward the central portion. The peripheral portion includes a first set of trusses having a first density of trusses, and the central portion includes a second set of trusses having a second density of trusses. The first density of trusses in the peripheral portion is greater than the second density of trusses in the central portion. The first set of trusses includes a first strut and a first node, and the second set of trusses includes a second strut, wherein the first node connects the first strut with the second strut.
In another aspect, an intervertebral implant includes an intervertebral implant comprising a body having an open truss structure, the body having a generally annular shape with opposing end surfaces, the opposing end surfaces including a superior surface and an inferior surface. The body may also have a perimeter surface, the perimeter surface extending around an outer periphery of the body. In addition, the body may have a central portion and a peripheral portion, the peripheral portion extending inward from the perimeter surface toward the central portion. Further, the peripheral portion may include a first set of trusses, the first set of trusses having a first density of trusses. Also, the central portion may include a second set of trusses, the second set of trusses having a second density of trusses. The first density of trusses in the peripheral portion is greater than the second density of trusses in the central portion, wherein the first set of trusses includes a first strut and a first node, wherein the second set of trusses includes a second strut, and wherein the first node connects the first strut with the second strut.
In another aspect, the present disclosure is directed to an intervertebral implant comprising a body having an open truss structure, the body having a generally annular shape with opposing end surfaces, the opposing end surfaces including a superior surface and an inferior surface. The body may also have a perimeter surface, the perimeter surface extending around an outer periphery of the body. In addition, the body may have a central portion and a peripheral portion, the peripheral portion extending inward from the perimeter surface toward the central portion, the central portion having a central axis. Also, the body may include a first strut disposed on the perimeter surface, and a second strut disposed inward of the perimeter surface so that the second strut is closer to the central axis than the first strut. The central axis and the second strut define a radial direction that extends from the central axis to the second strut. The second strut may have a non-circular cross-sectional shape with a cross-sectional length and a cross-sectional width, wherein the cross-sectional length is longer than the cross-sectional width, and wherein the cross-sectional length of the second strut extends along the radial direction.
In another aspect, the present disclosure is directed to a method of making an intervertebral implant having a body, the body having an open truss structure, the body including opposing end surfaces, and a perimeter surface, the perimeter surface extending around an outer periphery of the body; the body also including a central portion and a peripheral portion, the peripheral portion extending from the perimeter surface inward toward the central portion. The method of making may include additively manufacturing a first layer, the first layer being proximate a base plate; the first layer forming a part of the perimeter surface. The method may also include continuing to additively manufacture the body layer by layer wherein each successive layer is disposed further from the base plate than the previous layer so that the body is built vertically upward layer by layer. Further, the method may include additively manufacturing a lower peripheral portion, and additively manufacturing the peripheral portion and the central portion in the same layer, wherein this step occurs after the step of additively manufacturing the peripheral portion, and wherein less material is used to form the central portion than the peripheral portion so that a central truss structure is less dense than a peripheral truss structure. Also, the method may include additively manufacturing an upper peripheral portion.
Other systems, methods, features, and advantages of the embodiments will be, or will become, apparent to one of ordinary skill in the art upon examination of the following figures and detailed description. It is intended that all such additional systems, methods, features, and advantages be included within this description and this summary, be within the scope of the embodiments, and be protected by the following claims.
The embodiments can be better understood with reference to the following drawings and description. The components in the figures are not necessarily to scale, emphasis instead being placed upon illustrating the principles of the embodiments. Moreover, in the figures, like reference numerals designate corresponding parts throughout the different views.
Any of the embodiments described herein may make use of any of the body/support structures, frames, plates, coils, or other structures disclosed in:
The entire disclosures of the patents and publications listed above are incorporated herein by reference in their entirety.
For purposes of clarity, reference is made to various directional adjectives throughout the detailed description and in the claims. As used herein, the term “anterior” refers to a side or portion of an implant that is intended to be oriented toward the front of the human body when the implant has been placed in the body. Likewise, the term “posterior” refers to a side or portion of an implant that is intended to be oriented toward the back of the human body following implantation. In addition, the term “superior” refers to a side or portion of an implant that is intended to be oriented toward a top (e.g., the head) of the body while “inferior” refers to a side or portion of an implant that is intended to be oriented toward a bottom of the body. Reference is also made herein to “lateral” sides or portions of an implant, which are sides or portions facing along lateral directions of the body following implantation.
Implantation
For purposes of this disclosure, implant 100 may also be referred to as a cage or fusion device. In some embodiments, implant 100 is configured to be implanted within a portion of the human body. In some embodiments, implant 100 may be configured for implantation into the spine. In some embodiments, implant 100 may be a spinal fusion implant, or spinal fusion device, which is inserted between adjacent vertebrae to provide support and/or facilitate fusion between the vertebrae.
In some embodiments, implant 100 may be inserted using an anterior lumbar interbody fusion (ALIF) surgical procedure, where the disc space is fused by approaching the spine through the abdomen. In the ALIF approach, a three-inch to five-inch incision is typically made near the abdomen and the abdominal muscles are retracted to the side. In some cases, implant 100 can be inserted through a small incision in the front or anterior side of the body. In some cases, an anterior approach may afford improved exposure to the disc space to a surgeon. The anterior approach can allow a larger device to be used for the fusion, increasing the surface area for fusion to occur and allowing for more postoperative stability. An anterior approach often makes it possible to reduce some of the deformity caused by various conditions, such as isthmic spondylolisthesis. Insertion and placement of the implant can also re-establish the patient's normal sagittal alignment in some cases, giving individuals a more normal inward curve to their low back.
In some embodiments, the implant may be configured for insertion via a non-ALIF pathway. For example, in some embodiments, the implant may be configured for insertion via an oblique pathway, a lateral pathway, or any other pathway for inserting an intervertebral implant.
Introduction to Implant
Implant 100 may also be associated with various edges that are located at the intersections between various sides. For example, superior side 130 and first lateral side 114 may meet at a superior-lateral edge. Likewise, inferior side 140 and first lateral side 114 may meet at an inferior-lateral edge. It may be appreciated that the term “edge” as used herein is not limited to a precise contour of implant 100 and is used instead to refer to a general region proximate the intersection of two sides or faces of implant 100.
Reference is also made to directions or axes that are relative to the implant itself, rather than to its intended orientation with regards to the body. For example, the term “central” refers to a part that is located closer to the center of the implant. As used herein, the “center of the implant” is generally defined as a vertical axis extending through the approximate middle of the implant, which may be approximately the location of the center of mass or the dimensional middle (i.e., equidistant from opposing sides.
An implant may also be associated with various axes. Referring to
An implant may also be associated with various reference planes or surfaces. As used herein, the term “median plane” refers to a vertical plane that passes from the anterior side to the posterior side of the implant, dividing the implant into right and left halves, or lateral halves. As used herein, the term “transverse plane” refers to a horizontal plane located in the center of the implant that divides the implant into superior and inferior halves. As used herein, the term “coronal plane” refers to a vertical plane located in the center of the implant that divides the implant into anterior and posterior halves. In some embodiments, the implant is symmetric about two planes, such as the transverse plane.
Implant 100 is comprised of one or more body members attached to one or more bone contacting elements. In the embodiments shown in
Some embodiments can include one or more fastener-receiving provisions. In some embodiments, an implant can include one or more threaded cavities. In some embodiments, a threaded cavity can be configured to mate with a corresponding threaded tip on an implantation tool or device. In other embodiments, a threaded cavity can receive a fastener for purposes of fastening an implant to another device or component in an implantation system that uses multiple implants and/or multiple components.
As best seen in
In the exemplary embodiment, first body member 120 and screw plates 530 are disposed at an anterior end of implant 100. This configuration facilitates an ALIF approach to implantation of implant 100. Alternatively, in other embodiments, implant 100 could comprise one or more body members and/or screw plates on first lateral side 114, on second lateral side 116, and/or at an oblique angle in order to facilitate implantation from a non-ALIF approach.
In some embodiments, variations in height or vertical thickness between anterior side 110 and posterior side 112 may allow for an implant with hyper-lordotic angles between the inferior and superior surfaces. In other embodiments, variations in vertical thickness may be used to control the relative rigidity of the device in different locations. In other embodiments, implant 100 may have similar heights at anterior side 110 and posterior side 112.
In some embodiments, implant 100 may include one or more bone contacting elements or struts 160 that may be attached, and/or continuously formed with one another. As used herein, each bone contacting element comprises a distinctive member or element that spans a region or area of an implant. In some embodiments, these elements may overlap or intersect, similar to elements in a lattice or other 3D mesh structure. In other embodiments, the elements may not overlap or intersect. Some embodiments may use elongated elements, in which the length of the element is greater than its width and its thickness. For example, in embodiments where an element has an approximately circular cross-sectional shape, the element has a length greater than its diameter. In the embodiments seen in
Geometry of Bone Contacting Elements
Embodiments can include provisions for protecting bone growth along and adjacent to bone contacting elements of an implant. In some embodiments, a bone contacting element can be configured with a geometry that helps to protect new bone growth in selected regions that may be referred to as “protected fusion zones.” In a protected fusion zone, new bone growth may be partially protected from forces transmitted directly between vertebrae and bone contacting surfaces of an implant, thereby increasing the rate at which new bone growth may propagate through the implant.
In some embodiments, a bone contacting element can have a spiral, helical or twisted geometry that provide a series of such protected fusion zones for enhanced bone growth. In other embodiments, a bone contacting element can have a planar undulating geometry (e.g., sinusoidal) that may also create protected fusion zones. In some embodiments, an implant may include bone contacting elements with a helical geometry and other bone contacting elements with a sinusoidal or planar undulating geometry.
Some bone contacting elements may have a generalized helical geometry. As used herein, a “generalized helical geometry” or “spiraling geometry” refers to a geometry where a part (portion, member, etc.) winds, turns, twists, rotates, or is otherwise curved around a fixed path. In some cases, the fixed path could be straight. In other cases, the fixed path can be curved. In the present embodiments, for example, the fixed path is generally a combination of straight segments and curved segments.
Curves having a generalized helical geometry (also referred to as generalized helical curves) may be characterized by “coils”, “turns,” or “windings” about a fixed path. Exemplary parameters that may characterize the specific geometry of a generalized helical curve can include coil diameter (including both a major and minor diameter) and the pitch (i.e., spacing between adjacent coils). In some cases, the “amplitude” of a coil or loop may also be used to describe the diameter or widthwise dimension of the coil or loop. Each of these parameters could be constant or could vary over the length of a generalized helical curve.
Generalized helical curves need not be circular or even round. In some embodiments, for example, a generalized helical curve could have a linearly segmented shape (or locally polygonal shape) such that each “coil” or “turn” is comprised of straight line segments rather than arcs or other curved segments. Generalized helical curves may also include combinations of curved and straight segments.
For purposes of characterizing the geometry of helical bone contacting elements, each bone contacting element can be identified with one or more curves. Each bone contacting element may be identified with a central curve. The central curve of each bone contacting element may be defined as a curve that extends along the length (or longest dimension) of the bone contacting element such that each point along the curve is centrally positioned within the bone contacting element. In addition, each bone contacting element may be identified with one or more exterior surface curves. An exterior surface curve of a bone contacting element may be defined as a curve that extends along the length (or longest dimension) of the bone contacting element such that each point along the curve is positioned on the exterior surface.
In some cases, bone graft material may be used with the disclosed implants. For purposes of this disclosure and claims, the term “bone graft material” shall include any type of bone graft material, including harvested bone graft material and/or bone graft substitute. A variety of materials may serve as bone grafts or bone graft substitutes, including autografts (harvested from the iliac crest of the patient's body), allografts, demineralized bone matrix, and various synthetic materials.
Some embodiments may use autograft as a bone graft material. Autograft provides the spinal fusion with calcium collagen scaffolding for the new bone to grow on (osteoconduction). Additionally, autograft contains bone-growing cells, mesenchymal stem cells and osteoblast that regenerate bone. Lastly, autograft contains bone-growing proteins, including bone morphogenic proteins (BMPs), to foster new bone growth in the patient.
Bone graft substitutes may comprise synthetic materials including calcium phosphates or hydroxyapatites, stem cell containing products that combine stem cells with one of the other classes of bone graft substitutes, and growth factor containing matrices such as INFUSE® (rhBMP-2-containing bone graft) from Medtronic, Inc.
It should be understood that the provisions listed here are not meant to be an exhaustive list of possible bone graft materials.
As also shown in
In addition, as also shown in
A number of factors may influence the ease and extent to which bone graft material may flow into the spaces within the truss structure of the implant. For example, the viscosity and composition of the bone graft material can affect the introduction of bone graft material into the implant. Higher viscosity of the bone graft material and larger solid pieces of bone and bone substitute may reduce the ease with which bone graft material may flow generally. In addition, the density of the truss structure affects the size of the openings through which the bone graft material must flow, and thus, can influence the flow of material into the implant.
In some embodiments, the implant may include provisions to facilitate the introduction of bone graft material into the implant between the struts. For example, in some embodiments, the density of struts and/or trusses may differ in different portions of the implant. In some cases, the central portion may have a lower density of struts than the peripheral portion. In such embodiments, the higher density of struts in the peripheral portion may provide load bearing support around the periphery of adjacent vertebrae, which is typically a more structurally robust type of bone, like cortical bone. The lower density of struts in the central portion may facilitate the introduction of bone graft material, which promotes fusion of the adjacent vertebrae between which the implant is inserted.
As shown in in
Struts 160 forming the open lattice structure of body 502 of implant 100 are generally elongate members having a longitudinal length and a lateral width, with the longitudinal length being longer than the lateral width. Struts 160 can include one or more outer struts 512 and one or more inner struts 514. In this embodiment, outer struts 512 are disposed along the perimeter edge of implant 100 and define the boundary of peripheral portion 154. Outer struts 512 can include substantially straight segments and/or curved or arched segments. In some embodiments, outer struts 512 may include combinations of curved and straight segments that assist with providing and defining the overall shape of implant 100.
Inner struts 514 extend from the perimeter edge of implant 100 defined by outer struts 512 inward toward central portion 152 of body 502. Inner struts 514 intersect with one another at one or more nodes 520. A plurality of inner struts 514 intersects at a plurality of nodes 520 to collectively form the open lattice structure of body 502. In this embodiment, inner struts 514 are substantially straight segments. In other embodiments, inner struts 514 can include substantially straight segments, curved or arched segments, and/or a combination of curved and straight segments to form an open lattice structure.
In some embodiments, the implant may include provisions to facilitate spread of bone graft material from the central portion radially outward into the peripheral portion of the implant. For example, in some embodiments, the implant may include an interface portion between the central portion and the peripheral portion. For example, the interface portion may be a boundary of truss units defining a boundary between the central portion and the peripheral portion. Each of these truss units may be arranged in a generally vertical orientation in a substantially vertical plane. Truss units forming the perimeter surface of the implant may also be arranged in a substantially vertical plane. Thus, the truss units of the interface portion may be arranged in planes that are substantially parallel to planes in which the truss units of the perimeter surface are arranged. In order to facilitate spread of bone graft material from the central portion through the truss units of the interface portion into the peripheral portion, the density of struts in the interface portion may be less than the density of struts in the perimeter surface. For example, in some embodiments, the density of truss units in the interface portion may be less than the density of truss units in the perimeter surface.
As further shown in
In some cases, the implant may include provisions to facilitate the flow of bone graft material past the struts, such as the interface struts. For example, in some embodiments, the struts may be provided with a non-circular cross-sectional shape. In some embodiments, the struts may have an oblong cross-sectional shape. By having an oblong cross-sectional shape, the width of the strut may be made reduced in one direction while still maintaining the same cross-sectional area. The reduced width of the strut may enable more flow of bone graft material past the strut. Further, the bone graft material may converge behind the strut more readily after flowing past it, thus filling the volume behind the strut more completely. In some embodiments, the struts may not only be oblong, but may also include further provisions to facilitate convergence of the bone graft material behind the strut. For example, in some embodiments, the struts may have a substantially airfoil cross-sectional shape. The airfoil cross-sectional shape may provide the struts with a narrower width to reduce the obstruction to flow by increasing the size of the passages between struts, as well as a tapered profile to facilitate convergence of the bone graft material behind the strut as the bone graft material flows past the struts.
The airfoil shape illustrated in the accompanying drawings is intended to be relatively generic. Struts may have any of a number of different airfoil cross-sectional shapes. Exemplary airfoils may be concave, convex, or may simply have a trailing portion with a consistent taper. In some cases, the sides of the airfoil may be shaped differently in order to direct the flow of bone graft material in a particular direction. The airfoils may also be oriented in a variety of directions. In some cases, the long axis of the airfoil may be oriented substantially radially with respect to the central axis of the implant, and thus, in the direction of flow of bone graft material. In other cases, one or more airfoil-shaped struts may be oriented with the cross-sectional length oriented at a non-zero angle with respect to the direction of flow. Non-zero angle orientations may be implemented to redirect flow of bone graft material to particular portions of the implant's inner volume. For example, in some embodiments, the cross-sectional length of the struts may be oriented at an angle with respect to the radial direction of the implant. In such embodiments, when bone graft material is introduced into the central portion of the implant and flows radially outward, the non-circular struts oriented at non-zero angles may redirect the radial flow into predetermined regions of the implant. In some embodiments, the interface struts may have different shapes and orientations from one another.
The longitudinal length of non-circular struts may be oriented at non-zero angles with respect to horizontal. For example, in some embodiments, not only vertically oriented struts, but also diagonally oriented interface struts may have non-circular cross-sectional shapes. Also, non-circular struts may be inclined along the cross-sectional length. In addition, it will be noted that other struts of the disclosed implant besides the interface struts between the central portion and the peripheral portion of the implant may have oblong or airfoil cross-sectional shapes. For example, in some embodiments, struts forming the superior surface of the central portion of the implant may have an oblong or airfoil cross-sectional shape with a cross-sectional length oriented substantially vertically. Such struts would facilitate the introduction of bone graft material into the central portion of the implant. In some embodiments, the struts forming the superior surface of the central portion of the implant may have non-circular cross-sectional shapes with their cross-sectional lengths oriented non-vertically in order to direct the flow of bone graft material to desired areas of the internal volume of the implant.
In some embodiments, non-circular struts may be inclined along the cross-sectional length. For example,
Struts having different orientations and/or cross-sectional shapes may be used in any suitable areas of the implant in order to provide the desired characteristics, such as strength, rigidity, flow of bone graft material, bone attachment, and other performance characteristics. In some embodiments, non-circular struts having different cross-sectional shapes and/or orientations as described above may be used within the same implant in different areas.
Body 202 may include a first strut 250 disposed on perimeter surface 235. Body 202 may also include a second strut 260 disposed inward of perimeter surface 235 so that second strut 260 is closer to central axis 215 than first strut 250. Central axis 215 and second strut 260 define a radial direction that extends from central axis 215 to second strut 260 as indicated by a radial axis 265 in
As shown in
As also shown in
In some embodiments, second strut 260 and/or third strut 270 may be inclined with respect to first strut 250. For example, second strut 260 and/or third strut 270 may be oriented at a non-vertical angle (see, e.g.,
The side profile of the implants shown in
In addition, as shown in
Peripheral portion 754 may include a first set of trusses having a first density of trusses. Central portion 752 may include a second set of trusses having a second density of trusses. Similar to the embodiments discussed above, the first density of trusses in peripheral portion 754 may be greater than the second density of trusses in central portion 752. This may facilitate introduction of bone graft material into the inner volume of implant 700.
As shown in
In some embodiments, peripheral portion 754 may be sized and configured to generally correspond to a region of denser bone, such as a cortical bone region of a confronting vertebral body. Accordingly, central portion 752 may be sized and configured to generally correspond to a region of bone that is less dense, such as a cancellous bone region of a confronting vertebral body.
In addition, in some embodiments, implant 700 may have an asymmetrical truss structure in central portion 752. For example, as shown in
Manufacturing and Materials
The various components of an implant may be fabricated from biocompatible materials suitable for implantation in a human body, including but not limited to, metals (e.g. titanium or other metals), synthetic polymers, ceramics, and/or their combinations, depending on the particular application and/or preference of a medical practitioner.
Generally, the implant can be formed from any suitable biocompatible, non-degradable material with sufficient strength. Typical materials include, but are not limited to, titanium, biocompatible titanium alloys (e.g., γTitanium Aluminides, Ti6—Al4—V ELI (ASTM F 136), or Ti6—Al4—V (ASTM F 1108 and ASTM F 1472)) and inert, biocompatible polymers, such as polyether ether ketone (PEEK) (e.g., PEEK-OPTIMA®, Invibio Inc). Optionally, the implant contains a radiopaque marker to facilitate visualization during imaging.
In different embodiments, processes for making an implant can vary. In some embodiments, the entire implant may be manufactured and assembled via injection-molding, cast or injection molding, insert-molding, co-extrusion, pultrusion, transfer molding, overmolding, compression molding, 3-Dimensional (3-D) printing, dip-coating, spray-coating, powder-coating, porous-coating, milling from a solid stock material and their combinations. In some cases, the implant may be formed by additive manufacturing (e.g., 3-D printing) in an anatomical orientation. That is, the implant may be formed from the bottom up in its regular upright position. However, in other cases, the implant may be formed by an additive manufacturing process in a non-anatomical orientation. For example, in some cases, the implant may be formed on its side. For instance, in some cases, the implant may be formed beginning with the anterior surface and concluding with the posterior surface. In some cases, the implant may be formed beginning with one lateral side and concluding with the opposing lateral side.
Provisions may be used to facilitate additive manufacturing in one or more particular orientations. For example, in some cases, additive manufacturing may be facilitated by the orientations of the struts. For example, in the orientation in which the implant is desired to be manufactured, the roof angle, i.e., the angle between the underside of a structural component and a horizontal plane, may be 30 degrees or greater. In some embodiments, the minimum roof angle may be 32 degrees.
Alternatively, or additionally, closely spaced, paper-thin vertical elements may be printed as a supportive base in order to additively manufacture structures with a roof angle of less than 30 degrees. With the vertical elements so closely spaced, there is a small enough span between the vertical elements that the horizontal structures can be added despite having a roof angle smaller than 30 degrees. Because the vertical elements are so thin, they can be easily broken away from the completed implant after the additive manufacturing process has been complete. That is, the vertical elements can be “knock-outs” or “punch-out” elements that are removed after manufacturing.
Referring now to
According to the exemplary process, an implant, for example, implant 100, described above, is printed in a substantially vertical direction. That is, the implant is printed in a direction starting at one end along the perimeter surface of the implant (e.g., the anterior side) and continuing to add layers until forming the opposite end of the perimeter surface (e.g., the posterior side). The exemplary process described here is in contrast to printing the implant oriented in a substantially horizontal (anatomical) direction, which would be in a direction starting at the contact surface on the superior or inferior side of the implant (i.e., the top or bottom of the implant) and continuing to add layers until forming the contact surface on the opposite side of the implant.
With the exemplary process, each of the inferior and superior surfaces on opposite sides of the implant are formed in a substantially vertical direction simultaneously such that each successive layer adds material to both the inferior and superior surfaces on opposite sides of the implant during the same pass of the additive manufacturing tool.
Referring now to
During the exemplary manufacturing process, the process involves continuing to additively manufacture the body layer by layer wherein each successive layer is disposed further from base plate 410 than the previous layer so that the body is built vertically upward, layer by layer. Accordingly, additional layers of material are built up in the vertical direction by multiple passes, with each pass adding material to the first layer and subsequent additional layers to continue to form implant 100. As shown in
During the substantially vertical manufacturing, the contact surfaces on opposite sides (superior and inferior) of implant 100 are formed in layers such that material is added to both sides during the same pass of the additive manufacturing process. For example, in
In addition, the additive manufacturing process described above can provide texture or other surface irregularities to both bone contacting surfaces (i.e., superior surface 141 and inferior surface 142) during the 3D manufacturing process. If the implant were to be formed with the inferior surface on the baseplate 410, then inferior surface 142 would have a flat, non-textured finish. However, by forming the implant starting on the anterior side and progressing in the posterior direction, texture may be formed on both the superior and inferior sides of the implant. Such texture or surface irregularities may assist with providing greater adhesion in contact with a bone of a patient.
Thus, the process may involve additively manufacturing a lower peripheral portion of the implant (i.e., an area of the peripheral portion disposed closest to the baseplate, such as the anterior part of the peripheral portion). The process may then involve additively manufacturing parts of the peripheral portion and the central portion together in the same additive layer, such that this step occurs after the step of additively manufacturing the lower peripheral portion. It will be noted that less material may be used to form the central portion than the peripheral portion so that a central truss structure is less dense than a peripheral truss structure. Subsequently, the process may involve additively manufacturing an upper peripheral portion.
As shown in
As shown in
In order to facilitate the additive manufacturing of implant 2600, one or more thin vertical elements 2610 may be formed on baseplate 2605. Implant 2600 may be formed on a bed of thin vertical elements 2610. This enables the horizontally oriented surface of anterior side 2615 of implant 2600 to be formed despite having a roof angle of less than 30 degrees. Thin vertical elements 2610 are formed close enough together that the horizontally oriented surface of anterior side 2615 can be formed by additive manufacturing. By forming anterior side 2615 lifted off baseplate 2605, various surface features, such as texture, may be formed on the surface of anterior side 2615 during the additive manufacturing process.
In addition, the structural elements of implant 2600 may have a minimum roof angle of 30 degrees. For example, as illustrated in
While
In addition, as also shown in
It will also be understood that, in addition to the peripheral structures, the internal structures of implant 2600 may also have minimum roof angles of 30 degrees or more. For example, as shown in
In addition, internal posterior structures, such as a posterior structure 2685, may have roof angles of 30 degrees or more. Posterior structure 2685 may have a first anterior-facing surface 2690 and a second anterior-facing surface 2695. As shown in
While various embodiments have been described, the description is intended to be exemplary, rather than limiting, and it will be apparent to those of ordinary skill in the art that many more embodiments and implementations are possible that are within the scope of the embodiments. Although many possible combinations of features are shown in the accompanying figures and discussed in this detailed description, many other combinations of the disclosed features are possible. Any feature of any embodiment may be used in combination with or substituted for any other feature or element in any other embodiment unless specifically restricted. Therefore, it will be understood that any of the features shown and/or discussed in the present disclosure may be implemented together in any suitable combination. Accordingly, the embodiments are not to be restricted except in light of the attached claims and their equivalents. Also, various modifications and changes may be made within the scope of the attached claims.
Number | Name | Date | Kind |
---|---|---|---|
3720959 | Hahn | Mar 1973 | A |
4038703 | Bokros | Aug 1977 | A |
4309777 | Patil | Jan 1982 | A |
4759769 | Hedman | Jul 1988 | A |
4851008 | Johnson | Jul 1989 | A |
4889685 | Shimamune | Dec 1989 | A |
4917704 | Frey | Apr 1990 | A |
4961740 | Ray et al. | Oct 1990 | A |
5055104 | Ray | Oct 1991 | A |
5198308 | Shetty et al. | Mar 1993 | A |
5263953 | Bagby | Nov 1993 | A |
5306310 | Siebels | Apr 1994 | A |
5397359 | Mittelmeier | Mar 1995 | A |
5423817 | Lin | Jun 1995 | A |
5458638 | Kuslich et al. | Oct 1995 | A |
5571185 | Schug | Nov 1996 | A |
5571192 | Schonhoffer | Nov 1996 | A |
5607424 | Tropiano | Mar 1997 | A |
5609635 | Michelson | Mar 1997 | A |
5609636 | Kohrs | Mar 1997 | A |
5658337 | Kohrs et al. | Aug 1997 | A |
5709683 | Bagby | Jan 1998 | A |
5716416 | Lin | Feb 1998 | A |
D403069 | Drewry et al. | Dec 1998 | S |
5885299 | Winslow | Mar 1999 | A |
5888223 | Bray, Jr. | Mar 1999 | A |
5897556 | Drewry et al. | Apr 1999 | A |
5954504 | Misch et al. | Sep 1999 | A |
5968098 | Winslow | Oct 1999 | A |
5973222 | Devanathan et al. | Oct 1999 | A |
6010502 | Bagby | Jan 2000 | A |
6039762 | McKay | Mar 2000 | A |
6090143 | Meriwether et al. | Jul 2000 | A |
6102948 | Brosnahan, III | Aug 2000 | A |
6126689 | Brett | Oct 2000 | A |
6149651 | Drewry et al. | Nov 2000 | A |
6156037 | LeHuec et al. | Dec 2000 | A |
6200348 | Biedermann et al. | Mar 2001 | B1 |
6206924 | Timm | Mar 2001 | B1 |
6210412 | Michelson | Apr 2001 | B1 |
6371987 | Weiland et al. | Apr 2002 | B1 |
6428575 | Koo et al. | Aug 2002 | B2 |
6436141 | Castro et al. | Aug 2002 | B2 |
6464727 | Sharkey | Oct 2002 | B1 |
6468309 | Lieberman | Oct 2002 | B1 |
6494883 | Ferree | Dec 2002 | B1 |
6500205 | Michelson | Dec 2002 | B1 |
6520996 | Manasas et al. | Feb 2003 | B1 |
6527805 | Studer et al. | Mar 2003 | B2 |
6530956 | Mansmann | Mar 2003 | B1 |
6537320 | Michelson | Mar 2003 | B1 |
6558423 | Michelson | May 2003 | B1 |
6569201 | Moumene | May 2003 | B2 |
6582431 | Ray | Jun 2003 | B1 |
6582467 | Teitelbaum et al. | Jun 2003 | B1 |
6585770 | White et al. | Jul 2003 | B1 |
6616695 | Crozet et al. | Sep 2003 | B1 |
6666888 | Jackson | Dec 2003 | B1 |
6709458 | Michelson | Mar 2004 | B2 |
6758849 | Michelson | Jul 2004 | B1 |
6808537 | Michelson | Oct 2004 | B2 |
6846327 | Khandkar et al. | Jan 2005 | B2 |
6849093 | Michelson | Feb 2005 | B2 |
6863689 | Ralph et al. | Mar 2005 | B2 |
6923810 | Michelson | Aug 2005 | B1 |
6962606 | Michelson | Nov 2005 | B2 |
6997953 | Chung et al. | Feb 2006 | B2 |
7135043 | Nakahara et al. | Nov 2006 | B2 |
7141068 | Ross et al. | Nov 2006 | B2 |
7153325 | Kim et al. | Dec 2006 | B2 |
7186267 | Aston et al. | Mar 2007 | B2 |
7241313 | Unwin et al. | Jul 2007 | B2 |
7261739 | Ralph | Aug 2007 | B2 |
7297162 | Mujwid | Nov 2007 | B2 |
7341601 | Eisermann et al. | Mar 2008 | B2 |
7410501 | Michelson | Aug 2008 | B2 |
7429270 | Baumgartner et al. | Sep 2008 | B2 |
7435261 | Castro | Oct 2008 | B1 |
7452369 | Barry | Nov 2008 | B2 |
7465318 | Sennett | Dec 2008 | B2 |
7485134 | Simonson | Feb 2009 | B2 |
7527649 | Blain | May 2009 | B1 |
7534254 | Michelson | May 2009 | B1 |
7537603 | Huebner et al. | May 2009 | B2 |
7537616 | Branch et al. | May 2009 | B1 |
7575598 | Albert | Aug 2009 | B2 |
7611217 | Shamoun et al. | Nov 2009 | B2 |
7621952 | Truckai et al. | Nov 2009 | B2 |
7621953 | Braddock, Jr. et al. | Nov 2009 | B2 |
7628814 | Studer et al. | Dec 2009 | B2 |
7645475 | Prewett | Jan 2010 | B2 |
7655043 | Peterman et al. | Feb 2010 | B2 |
7794500 | Felix | Sep 2010 | B2 |
7799056 | Sankaran | Sep 2010 | B2 |
7803191 | Biedermann et al. | Sep 2010 | B2 |
7815665 | Jahng | Oct 2010 | B2 |
7846207 | Lechmann et al. | Dec 2010 | B2 |
7875075 | Schwab | Jan 2011 | B2 |
7879100 | Denoziere | Feb 2011 | B2 |
7879103 | Gertzman et al. | Feb 2011 | B2 |
7935149 | Michelson | May 2011 | B2 |
8016887 | Castro | Sep 2011 | B1 |
8021424 | Beger et al. | Sep 2011 | B2 |
8021426 | Segal et al. | Sep 2011 | B2 |
8062365 | Schwab | Nov 2011 | B2 |
8092536 | Ahrens et al. | Jan 2012 | B2 |
8142507 | McGuckin, Jr. | Mar 2012 | B2 |
8152849 | Biedermann et al. | Apr 2012 | B2 |
8182538 | O'Neil et al. | May 2012 | B2 |
8226718 | Castro | Jul 2012 | B2 |
8241363 | Sommerich et al. | Aug 2012 | B2 |
8246683 | Castro | Aug 2012 | B2 |
8252059 | Overes et al. | Aug 2012 | B2 |
8298286 | Trieu | Oct 2012 | B2 |
8303879 | Bertele et al. | Nov 2012 | B2 |
8343224 | Lynn | Jan 2013 | B2 |
8361149 | Castro | Jan 2013 | B2 |
8366777 | Matthis et al. | Feb 2013 | B2 |
D681204 | Farris et al. | Apr 2013 | S |
8414654 | Ganey | Apr 2013 | B1 |
8414820 | Bertele et al. | Apr 2013 | B2 |
8430930 | Hunt | Apr 2013 | B2 |
D681812 | Farris et al. | May 2013 | S |
8435300 | Messerli et al. | May 2013 | B2 |
8454700 | Lemoine et al. | Jun 2013 | B2 |
8475533 | Castro | Jul 2013 | B1 |
8551173 | Lechmann et al. | Oct 2013 | B2 |
8556978 | Schaller | Oct 2013 | B2 |
8568413 | Mazur et al. | Oct 2013 | B2 |
8613769 | Sears et al. | Dec 2013 | B2 |
8623090 | Butler | Jan 2014 | B2 |
8673006 | Castro | Mar 2014 | B2 |
8700198 | Conway et al. | Apr 2014 | B2 |
8702808 | Teoh et al. | Apr 2014 | B2 |
8709042 | Greenhalgh et al. | Apr 2014 | B2 |
8728160 | Globerman | May 2014 | B2 |
8740981 | Tornier et al. | Jun 2014 | B2 |
8771357 | Biedermann et al. | Jul 2014 | B2 |
8771368 | McKay | Jul 2014 | B2 |
8795362 | Anderson et al. | Aug 2014 | B2 |
8801787 | Schaller | Aug 2014 | B2 |
8808376 | Schaller | Aug 2014 | B2 |
8808725 | Altschuler et al. | Aug 2014 | B2 |
8840614 | Mikhail et al. | Sep 2014 | B2 |
8864831 | Lee et al. | Oct 2014 | B2 |
8894661 | McDevitt | Nov 2014 | B2 |
8900310 | Carlson | Dec 2014 | B2 |
8900312 | McLean et al. | Dec 2014 | B2 |
8932356 | Kraus | Jan 2015 | B2 |
8940050 | Laurence | Jan 2015 | B2 |
8940052 | Lechmann et al. | Jan 2015 | B2 |
8951300 | Parrish | Feb 2015 | B2 |
8986383 | Castro | Mar 2015 | B2 |
9011499 | Kiester | Apr 2015 | B1 |
9039766 | Fonte | May 2015 | B1 |
9060876 | To | Jun 2015 | B1 |
9101491 | Rodgers | Aug 2015 | B2 |
D739935 | Blain et al. | Sep 2015 | S |
9138301 | Kita et al. | Sep 2015 | B2 |
9155819 | Fonte et al. | Oct 2015 | B2 |
9186252 | Leibinger | Nov 2015 | B2 |
9186257 | Geisler et al. | Nov 2015 | B2 |
9220518 | Neal et al. | Dec 2015 | B2 |
9237958 | Duggal et al. | Jan 2016 | B2 |
9247970 | Teisen | Feb 2016 | B2 |
9254199 | Biedermann et al. | Feb 2016 | B2 |
9271765 | Blain | Mar 2016 | B2 |
9271771 | Mathieu et al. | Mar 2016 | B2 |
9271845 | Hunt et al. | Mar 2016 | B2 |
9289308 | Marino et al. | Mar 2016 | B2 |
9289312 | Davenport et al. | Mar 2016 | B2 |
9295552 | Lechmann et al. | Mar 2016 | B2 |
9364330 | Lindsey et al. | Jun 2016 | B2 |
9402733 | To et al. | Aug 2016 | B1 |
9408651 | Sennett et al. | Aug 2016 | B2 |
9421108 | Hunt | Aug 2016 | B2 |
9427328 | Drochner | Aug 2016 | B2 |
9433510 | Lechmann et al. | Sep 2016 | B2 |
9433511 | Bagga et al. | Sep 2016 | B2 |
9439779 | Zhang et al. | Sep 2016 | B2 |
9439948 | Lin et al. | Sep 2016 | B2 |
9445317 | Dudda et al. | Sep 2016 | B2 |
9452056 | Early et al. | Sep 2016 | B2 |
9452064 | Trautwein et al. | Sep 2016 | B2 |
9456901 | Jones et al. | Oct 2016 | B2 |
9456907 | Castro | Oct 2016 | B1 |
9517095 | Vaidya | Dec 2016 | B2 |
9522028 | Warren et al. | Dec 2016 | B2 |
9526548 | Asfora | Dec 2016 | B2 |
9545317 | Hunt | Jan 2017 | B2 |
9549823 | Hunt et al. | Jan 2017 | B2 |
9554914 | Taylor et al. | Jan 2017 | B2 |
9561117 | Lechmann et al. | Feb 2017 | B2 |
9566095 | Lorio | Feb 2017 | B2 |
9566100 | Asfora | Feb 2017 | B2 |
9572669 | Hunt et al. | Feb 2017 | B2 |
9597197 | Lechmann et al. | Mar 2017 | B2 |
9603613 | Schoenefeld et al. | Mar 2017 | B2 |
9622880 | Dunworth et al. | Apr 2017 | B2 |
9629727 | Baynham | Apr 2017 | B2 |
9636226 | Hunt | May 2017 | B2 |
9649200 | Wickham | May 2017 | B2 |
9662128 | Reiley | May 2017 | B2 |
9662157 | Schneider et al. | May 2017 | B2 |
9662158 | Reiley | May 2017 | B2 |
9662224 | Weiman et al. | May 2017 | B2 |
9662226 | Wickham | May 2017 | B2 |
9668781 | Stark | Jun 2017 | B2 |
9675394 | Reiley | Jun 2017 | B2 |
9700356 | Donner et al. | Jul 2017 | B2 |
9744051 | Biedermann et al. | Aug 2017 | B2 |
9757235 | Hunt et al. | Sep 2017 | B2 |
9782270 | Wickham | Oct 2017 | B2 |
9788967 | Jo | Oct 2017 | B2 |
9814578 | Gotfried | Nov 2017 | B1 |
9907670 | DeRidder et al. | Mar 2018 | B2 |
9918849 | Morris et al. | Mar 2018 | B2 |
9931209 | Gotfried | Apr 2018 | B2 |
9987051 | Nunley et al. | Jun 2018 | B2 |
9987137 | Hunt et al. | Jun 2018 | B2 |
9999516 | Hunt | Jun 2018 | B2 |
10004546 | Gotfried | Jun 2018 | B2 |
10016279 | Castro | Jul 2018 | B1 |
10058433 | Lechmann et al. | Aug 2018 | B2 |
10064737 | Tsai et al. | Sep 2018 | B2 |
10098754 | Larsson | Oct 2018 | B2 |
10117746 | Cordaro | Nov 2018 | B2 |
10143569 | Weiman et al. | Dec 2018 | B2 |
10154913 | Steinmann et al. | Dec 2018 | B2 |
10159580 | Guizzardi et al. | Dec 2018 | B2 |
10182923 | Willis et al. | Jan 2019 | B2 |
10194962 | Schneider et al. | Feb 2019 | B2 |
10195524 | DeRidder et al. | Feb 2019 | B2 |
10213317 | Bishop et al. | Feb 2019 | B2 |
10226357 | Ries | Mar 2019 | B2 |
10254274 | Miklas et al. | Apr 2019 | B2 |
10265189 | Melkent et al. | Apr 2019 | B2 |
10271958 | Schaufler et al. | Apr 2019 | B2 |
10278833 | Howard et al. | May 2019 | B2 |
10278834 | Howard et al. | May 2019 | B2 |
10357377 | Nyahay et al. | Jul 2019 | B2 |
10368997 | Jones et al. | Aug 2019 | B2 |
10369009 | Joly et al. | Aug 2019 | B2 |
10413427 | Trieu | Sep 2019 | B2 |
10433977 | Lechmann et al. | Oct 2019 | B2 |
10433979 | Morris et al. | Oct 2019 | B2 |
10449051 | Hamzey et al. | Oct 2019 | B2 |
10449055 | McJunkin | Oct 2019 | B2 |
10449058 | Lechmann et al. | Oct 2019 | B2 |
10478312 | McShane, III et al. | Nov 2019 | B2 |
D870288 | Dang et al. | Dec 2019 | S |
10492921 | McShane, III et al. | Dec 2019 | B2 |
10507118 | Afzal | Dec 2019 | B2 |
10512549 | Bishop et al. | Dec 2019 | B2 |
10517739 | Ryan | Dec 2019 | B2 |
10524926 | Jasinski | Jan 2020 | B2 |
10524927 | Ryan | Jan 2020 | B2 |
10524929 | Shoshtaev | Jan 2020 | B2 |
10525688 | O'Neill et al. | Jan 2020 | B2 |
10531962 | Petersheim et al. | Jan 2020 | B2 |
10537666 | Paddock | Jan 2020 | B2 |
10555819 | Miccio | Feb 2020 | B2 |
10561456 | Cawley et al. | Feb 2020 | B2 |
10575965 | Kim et al. | Mar 2020 | B2 |
10588755 | Vogt et al. | Mar 2020 | B2 |
10617532 | Mazur et al. | Apr 2020 | B2 |
10624760 | Mirda et al. | Apr 2020 | B2 |
10660763 | Wilson et al. | May 2020 | B2 |
10660764 | Maglaras et al. | May 2020 | B2 |
10667924 | Nyahay et al. | Jun 2020 | B2 |
10675158 | Unger et al. | Jun 2020 | B2 |
10675385 | Barbas et al. | Jun 2020 | B2 |
10682238 | Petersheim et al. | Jun 2020 | B2 |
10695192 | Bishop et al. | Jun 2020 | B2 |
10709570 | Stauffer et al. | Jul 2020 | B2 |
10716678 | Stampfli et al. | Jul 2020 | B2 |
10722378 | Davis et al. | Jul 2020 | B2 |
10744001 | Sack | Aug 2020 | B2 |
10744003 | Ryan et al. | Aug 2020 | B2 |
10765530 | Steinmann et al. | Sep 2020 | B2 |
10772732 | Miller et al. | Sep 2020 | B1 |
D898197 | Cain | Oct 2020 | S |
10835388 | Milz et al. | Nov 2020 | B2 |
10849756 | Hunt et al. | Dec 2020 | B2 |
10856999 | Bishop et al. | Dec 2020 | B2 |
10940019 | Vishnubhotla et al. | Mar 2021 | B2 |
D920515 | Miller et al. | May 2021 | S |
D920516 | Miller et al. | May 2021 | S |
11026798 | Miller et al. | Jun 2021 | B1 |
11033394 | Hamzey et al. | Jun 2021 | B2 |
11065039 | McCormack | Jul 2021 | B2 |
11147679 | Kowalczyk et al. | Oct 2021 | B2 |
11160668 | Nyahay et al. | Nov 2021 | B2 |
D942011 | Cain | Jan 2022 | S |
11213405 | Bishop et al. | Jan 2022 | B2 |
D942623 | Cain | Feb 2022 | S |
D942624 | Cain | Feb 2022 | S |
D944400 | Cain | Feb 2022 | S |
11273048 | Cain et al. | Mar 2022 | B2 |
11452611 | McShane, III et al. | Sep 2022 | B2 |
20010014826 | Biedermann et al. | Aug 2001 | A1 |
20010032018 | Castro et al. | Oct 2001 | A1 |
20020052656 | Michelson | May 2002 | A1 |
20020120334 | Crozet | Aug 2002 | A1 |
20020123750 | Eisermann et al. | Sep 2002 | A1 |
20020183847 | Lieberman | Dec 2002 | A1 |
20030003127 | Brown et al. | Jan 2003 | A1 |
20030060825 | Alfaro | Mar 2003 | A1 |
20030078660 | Clifford et al. | Apr 2003 | A1 |
20030083746 | Kuslich | May 2003 | A1 |
20030109928 | Pasquet | Jun 2003 | A1 |
20030181913 | Lieberman | Sep 2003 | A1 |
20030236571 | Ralph | Dec 2003 | A1 |
20040059419 | Michelson | Mar 2004 | A1 |
20040082953 | Petit | Apr 2004 | A1 |
20040122518 | Rhoda | Jun 2004 | A1 |
20040193270 | DiMauro et al. | Sep 2004 | A1 |
20040210312 | Neumann | Oct 2004 | A1 |
20040225361 | Glenn et al. | Nov 2004 | A1 |
20050015154 | Lindsey et al. | Jan 2005 | A1 |
20050027364 | Kim | Feb 2005 | A1 |
20050143733 | Petit | Jun 2005 | A1 |
20050177238 | Khandkar et al. | Aug 2005 | A1 |
20050222681 | Richley et al. | Oct 2005 | A1 |
20050251260 | Gerber et al. | Nov 2005 | A1 |
20050278027 | Hyde, Jr. | Dec 2005 | A1 |
20050278028 | Mujwid | Dec 2005 | A1 |
20060041262 | Calvert et al. | Feb 2006 | A1 |
20060052872 | Studer | Mar 2006 | A1 |
20060052873 | Buck | Mar 2006 | A1 |
20060058881 | Trieu | Mar 2006 | A1 |
20060100706 | Shadduck et al. | May 2006 | A1 |
20060147332 | Jones et al. | Jul 2006 | A1 |
20060212118 | Abernathie | Sep 2006 | A1 |
20060217806 | Peterman | Sep 2006 | A1 |
20060293753 | Thramann | Dec 2006 | A1 |
20070027544 | McCord et al. | Feb 2007 | A1 |
20070179610 | Biedermann et al. | Aug 2007 | A1 |
20070198090 | Abdou | Aug 2007 | A1 |
20070260324 | Joshi et al. | Nov 2007 | A1 |
20080071356 | Greenhalgh | Mar 2008 | A1 |
20080167686 | Trieu | Jul 2008 | A1 |
20080183204 | Greenhalgh et al. | Jul 2008 | A1 |
20080255666 | Fisher | Oct 2008 | A1 |
20080288083 | Axelsson et al. | Nov 2008 | A1 |
20080300602 | Schmitt et al. | Dec 2008 | A1 |
20080306595 | McLeod et al. | Dec 2008 | A1 |
20080312742 | Abernathie | Dec 2008 | A1 |
20090030520 | Biedermann | Jan 2009 | A1 |
20090036985 | Whiting | Feb 2009 | A1 |
20090048675 | Bhatnagar et al. | Feb 2009 | A1 |
20090048678 | Saal et al. | Feb 2009 | A1 |
20090062917 | Foley et al. | Mar 2009 | A1 |
20090112321 | Kitchen | Apr 2009 | A1 |
20090149958 | Prewett et al. | Jun 2009 | A1 |
20090248162 | Peckham | Oct 2009 | A1 |
20100016974 | Janowski | Jan 2010 | A1 |
20100036498 | McDevitt | Feb 2010 | A1 |
20100057216 | Gannoe et al. | Mar 2010 | A1 |
20100137990 | Apatsidis | Jun 2010 | A1 |
20100145451 | Dee | Jun 2010 | A1 |
20100152856 | Overes | Jun 2010 | A1 |
20100161061 | Hunt | Jun 2010 | A1 |
20100185292 | Hochschuler | Jul 2010 | A1 |
20100228299 | Zrinski et al. | Sep 2010 | A1 |
20100286778 | Eisermann et al. | Nov 2010 | A1 |
20110015741 | Melkent et al. | Jan 2011 | A1 |
20110029085 | Hynes | Feb 2011 | A1 |
20110035019 | Goswami et al. | Feb 2011 | A1 |
20110066192 | Frasier et al. | Mar 2011 | A1 |
20110166660 | Laurence | Jul 2011 | A1 |
20110190888 | Bertele | Aug 2011 | A1 |
20110190895 | Segal et al. | Aug 2011 | A1 |
20110208311 | Janowski | Aug 2011 | A1 |
20110230970 | Lynn | Sep 2011 | A1 |
20110245926 | Kitchen | Oct 2011 | A1 |
20110270401 | McKay | Nov 2011 | A1 |
20110301709 | Kraus et al. | Dec 2011 | A1 |
20110313528 | Laubert | Dec 2011 | A1 |
20110313532 | Hunt | Dec 2011 | A1 |
20120010472 | Spann | Jan 2012 | A1 |
20120010717 | Spann | Jan 2012 | A1 |
20120150300 | Nihalani | Jun 2012 | A1 |
20120158143 | Shapiro | Jun 2012 | A1 |
20120191188 | Huang | Jul 2012 | A1 |
20120191189 | Huang | Jul 2012 | A1 |
20120220934 | Diener et al. | Aug 2012 | A1 |
20120232654 | Sharp et al. | Sep 2012 | A1 |
20120239150 | Ullrich | Sep 2012 | A1 |
20120285836 | von Oepen | Nov 2012 | A1 |
20120296431 | Kim | Nov 2012 | A1 |
20130030529 | Hunt | Jan 2013 | A1 |
20130096685 | Ciupik | Apr 2013 | A1 |
20130116793 | Kloss | May 2013 | A1 |
20130123935 | Hunt et al. | May 2013 | A1 |
20130158672 | Hunt | Jun 2013 | A1 |
20130184826 | Thaiyananthan | Jul 2013 | A1 |
20130190880 | Schaller | Jul 2013 | A1 |
20130021288 | Fonte | Aug 2013 | A1 |
20130218288 | Fonte | Aug 2013 | A1 |
20130226300 | Chataigner | Aug 2013 | A1 |
20130304211 | Trautwein et al. | Nov 2013 | A1 |
20140018814 | Gillard et al. | Jan 2014 | A1 |
20140018948 | Metzger | Jan 2014 | A1 |
20140052260 | McKenny | Feb 2014 | A1 |
20140058513 | Gahman et al. | Feb 2014 | A1 |
20140107785 | Geisler | Apr 2014 | A1 |
20140107786 | Geisler et al. | Apr 2014 | A1 |
20140114418 | Landry | Apr 2014 | A1 |
20140121776 | Hunt | May 2014 | A1 |
20140142707 | Compton et al. | May 2014 | A1 |
20140172111 | Lang et al. | Jun 2014 | A1 |
20140195005 | McKay | Jul 2014 | A1 |
20140228956 | Weiman | Aug 2014 | A1 |
20140228960 | Forterre | Aug 2014 | A1 |
20140243980 | Sack et al. | Aug 2014 | A1 |
20140249631 | Weiman | Sep 2014 | A1 |
20140277457 | Yeung et al. | Sep 2014 | A1 |
20140277464 | Richter et al. | Sep 2014 | A1 |
20140277569 | Lange | Sep 2014 | A1 |
20140288649 | Hunt | Sep 2014 | A1 |
20140288650 | Hunt | Sep 2014 | A1 |
20140303736 | Roussouly | Oct 2014 | A1 |
20140303745 | Anderson et al. | Oct 2014 | A1 |
20140309743 | Falahee | Oct 2014 | A1 |
20140336771 | Zambiasi | Nov 2014 | A1 |
20140358246 | Levy et al. | Dec 2014 | A1 |
20150045903 | Neal | Feb 2015 | A1 |
20150112351 | Hsu | Apr 2015 | A1 |
20150127106 | Partee et al. | May 2015 | A1 |
20150173910 | Siegal | Jun 2015 | A1 |
20150223951 | Bae et al. | Aug 2015 | A1 |
20150282944 | Guizzardi et al. | Oct 2015 | A1 |
20160008149 | Hsiao et al. | Jan 2016 | A1 |
20160015437 | Elleby et al. | Jan 2016 | A1 |
20160022430 | Wickham | Jan 2016 | A1 |
20160081809 | Schneider et al. | Mar 2016 | A1 |
20160166284 | Hacking et al. | Jun 2016 | A1 |
20160184103 | Fonte et al. | Jun 2016 | A1 |
20160193057 | Rhoda | Jul 2016 | A1 |
20160206439 | To et al. | Jul 2016 | A1 |
20160206440 | DeRidder et al. | Jul 2016 | A1 |
20160262903 | West | Sep 2016 | A1 |
20160270920 | Dawson et al. | Sep 2016 | A1 |
20160287388 | Hunt et al. | Oct 2016 | A1 |
20160287405 | Hunt et al. | Oct 2016 | A1 |
20160310294 | McConnell | Oct 2016 | A1 |
20160317320 | Ahn | Nov 2016 | A1 |
20160324656 | Morris et al. | Nov 2016 | A1 |
20160374727 | Greenhalgh et al. | Dec 2016 | A1 |
20170007409 | Mauldin et al. | Jan 2017 | A1 |
20170014235 | Jones et al. | Jan 2017 | A1 |
20170020685 | Geisler et al. | Jan 2017 | A1 |
20170042697 | McShane, III et al. | Feb 2017 | A1 |
20170049488 | Vestgaarden | Feb 2017 | A1 |
20170095337 | Pasini et al. | Apr 2017 | A1 |
20170095352 | Bruffey | Apr 2017 | A1 |
20170100167 | Lange et al. | Apr 2017 | A1 |
20170135706 | Frey et al. | May 2017 | A1 |
20170135733 | Donner et al. | May 2017 | A1 |
20170143383 | Ingalhalikar et al. | May 2017 | A1 |
20170151005 | Warren et al. | Jun 2017 | A1 |
20170156740 | Stark | Jun 2017 | A9 |
20170156766 | Anderson et al. | Jun 2017 | A1 |
20170156878 | Tsai | Jun 2017 | A1 |
20170156879 | Janowski | Jun 2017 | A1 |
20170156880 | Halverson et al. | Jun 2017 | A1 |
20170164979 | Donner et al. | Jun 2017 | A1 |
20170181784 | Li | Jun 2017 | A1 |
20170182222 | Paddock | Jun 2017 | A1 |
20170196693 | Jurick et al. | Jul 2017 | A1 |
20170216034 | Daniel | Aug 2017 | A1 |
20170216035 | Hunt | Aug 2017 | A1 |
20170239064 | Cordaro | Aug 2017 | A1 |
20170239066 | Walsh et al. | Aug 2017 | A1 |
20170258606 | Afzal | Sep 2017 | A1 |
20170319353 | Greenhalgh et al. | Nov 2017 | A1 |
20170348107 | Lee et al. | Dec 2017 | A1 |
20170348115 | Greenhalgh | Dec 2017 | A1 |
20180064540 | Hunt et al. | Mar 2018 | A1 |
20180085230 | Hunt | Mar 2018 | A1 |
20180110626 | McShane, III | Apr 2018 | A1 |
20180161477 | Nies | Jun 2018 | A1 |
20180221156 | Jones | Aug 2018 | A1 |
20180243104 | Garonzik | Aug 2018 | A1 |
20180256336 | Mueller et al. | Sep 2018 | A1 |
20180256352 | Nyahay et al. | Sep 2018 | A1 |
20180280139 | Jones | Oct 2018 | A1 |
20180289503 | Knapp | Oct 2018 | A1 |
20180296343 | Wei | Oct 2018 | A1 |
20180296350 | Hamzey et al. | Oct 2018 | A1 |
20180326493 | Gallagher et al. | Nov 2018 | A1 |
20180333272 | Mirda | Nov 2018 | A1 |
20180338838 | Cryder et al. | Nov 2018 | A1 |
20180368981 | Mattes et al. | Dec 2018 | A1 |
20180368991 | Levieux | Dec 2018 | A1 |
20190000636 | Kim et al. | Jan 2019 | A1 |
20190015209 | Seifert et al. | Jan 2019 | A1 |
20190038428 | Stauffer | Feb 2019 | A1 |
20190060079 | Unis et al. | Feb 2019 | A1 |
20190060083 | Weiman et al. | Feb 2019 | A1 |
20190076266 | Trudeau et al. | Mar 2019 | A1 |
20190083282 | Roeder et al. | Mar 2019 | A1 |
20190091027 | Asaad et al. | Mar 2019 | A1 |
20190133769 | Tetsworth et al. | May 2019 | A1 |
20190151109 | Arnin | May 2019 | A1 |
20190151113 | Sack | May 2019 | A1 |
20190159818 | Schneider et al. | May 2019 | A1 |
20190183653 | Gregersen et al. | Jun 2019 | A1 |
20190224023 | Howard et al. | Jul 2019 | A1 |
20190254840 | Gray et al. | Aug 2019 | A1 |
20190262139 | Wolters | Aug 2019 | A1 |
20190274841 | Hawkes et al. | Sep 2019 | A1 |
20190298542 | Kioss | Oct 2019 | A1 |
20190307574 | Nyahay et al. | Oct 2019 | A1 |
20190314169 | Patel et al. | Oct 2019 | A1 |
20190328546 | Palagi et al. | Oct 2019 | A1 |
20190336305 | Joly et al. | Nov 2019 | A1 |
20190343645 | Miccio et al. | Nov 2019 | A1 |
20190358058 | Trieu | Nov 2019 | A1 |
20190388238 | Lechmann et al. | Dec 2019 | A1 |
20200000603 | McJunkin | Jan 2020 | A1 |
20200036011 | Numata et al. | Jan 2020 | A1 |
20200038197 | Morris et al. | Feb 2020 | A1 |
20200038198 | Miccio | Feb 2020 | A1 |
20200086625 | O'Neill et al. | Mar 2020 | A1 |
20200113707 | Petersheim et al. | Apr 2020 | A1 |
20200113709 | Hsieh | Apr 2020 | A1 |
20200121470 | Moore et al. | Apr 2020 | A1 |
20200138595 | Shoshtaev et al. | May 2020 | A1 |
20200146842 | Jasinski | May 2020 | A1 |
20200155326 | Hunt | May 2020 | A1 |
20200179128 | Stalcup et al. | Jun 2020 | A1 |
20200179133 | Ryan | Jun 2020 | A1 |
20200188120 | Hamzey et al. | Jun 2020 | A1 |
20200188129 | McShane, III et al. | Jun 2020 | A1 |
20200188132 | Ryan | Jun 2020 | A1 |
20200188133 | McShane, III et al. | Jun 2020 | A1 |
20200190680 | Numata et al. | Jun 2020 | A1 |
20200197189 | Mazur et al. | Jun 2020 | A1 |
20200214852 | Tipping et al. | Jul 2020 | A1 |
20200222201 | Mirda et al. | Jul 2020 | A1 |
20200229940 | Bishop et al. | Jul 2020 | A1 |
20200229945 | Levieux | Jul 2020 | A1 |
20200237526 | Wilson et al. | Jul 2020 | A1 |
20200246160 | Zappacosta et al. | Aug 2020 | A1 |
20200261243 | Unger et al. | Aug 2020 | A1 |
20200268523 | Barthold et al. | Aug 2020 | A1 |
20200276019 | Shetty et al. | Sep 2020 | A1 |
20200281727 | Dang et al. | Sep 2020 | A1 |
20200297494 | Hunt et al. | Sep 2020 | A1 |
20200297505 | McLaughlin | Sep 2020 | A1 |
20200315812 | Davis et al. | Oct 2020 | A1 |
20200323645 | Northcutt et al. | Oct 2020 | A1 |
20200337851 | Stampfli et al. | Oct 2020 | A1 |
20200337855 | Stauffer et al. | Oct 2020 | A1 |
20200337856 | Moore et al. | Oct 2020 | A1 |
20200345506 | Ryan et al. | Nov 2020 | A1 |
20200352735 | Afzal | Nov 2020 | A1 |
20200375757 | Sack | Dec 2020 | A1 |
20200375758 | Northcutt et al. | Dec 2020 | A1 |
20200376174 | Melkent et al. | Dec 2020 | A1 |
20210022882 | Dang et al. | Jan 2021 | A1 |
20210046211 | Deisinger et al. | Feb 2021 | A1 |
20210069383 | Yamaguchi et al. | Mar 2021 | A1 |
20210085481 | Cain et al. | Mar 2021 | A1 |
20210307909 | Hamzey et al. | Oct 2021 | A1 |
20220047398 | Nyahay et al. | Feb 2022 | A1 |
20220071777 | Cain et al. | Mar 2022 | A1 |
20220117753 | Rucker et al. | Apr 2022 | A1 |
Number | Date | Country |
---|---|---|
101708138 | May 2010 | CN |
103932841 | Jul 2014 | CN |
204931903 | Jan 2016 | CN |
110179570 | Aug 2021 | CN |
19722389 | Dec 1998 | DE |
3064175 | Sep 2016 | EP |
3494931 | Jun 2019 | EP |
3517078 | Jul 2019 | EP |
3603580 | Feb 2020 | EP |
2815846 | May 2002 | FR |
2955025 | Jul 2011 | FR |
H05261146 | Oct 1993 | JP |
H09503416 | Sep 1997 | JP |
2001523129 | Nov 2001 | JP |
20010523129 | Nov 2001 | JP |
2004-510494 | Apr 2004 | JP |
2006515194 | May 2006 | JP |
2009-505686 | Feb 2009 | JP |
2009504332 | Feb 2009 | JP |
4313005 | Aug 2009 | JP |
2010137069 | Jun 2010 | JP |
201115959 | Jan 2011 | JP |
2012-501236 | Jan 2012 | JP |
2012501236 | Jan 2012 | JP |
20120501236 | Jan 2012 | JP |
5328051 | Oct 2013 | JP |
5455020 | Mar 2014 | JP |
2014-151209 | Aug 2014 | JP |
2015-502192 | Jan 2015 | JP |
2015502192 | Jan 2015 | JP |
5684177 | Mar 2015 | JP |
2015529150 | Oct 2015 | JP |
A2018-516646 | Jun 2018 | JP |
2019034071 | Mar 2019 | JP |
2019041886 | Mar 2019 | JP |
2019180797 | Oct 2019 | JP |
2019201688 | Nov 2019 | JP |
6700135 | May 2020 | JP |
2020199326 | Dec 2020 | JP |
2021016498 | Feb 2021 | JP |
WO 9510248 | Apr 1995 | WO |
WO 9848738 | Nov 1998 | WO |
WO 9852498 | Nov 1998 | WO |
WO 0209625 | Feb 2002 | WO |
WO 0234168 | May 2002 | WO |
WO 03099160 | Dec 2003 | WO |
WO 2004084774 | Oct 2004 | WO |
WO 2005011523 | Feb 2005 | WO |
WO 2009051779 | Mar 2006 | WO |
WO 2007022194 | Feb 2007 | WO |
WO 2009051779 | Apr 2009 | WO |
WO 2010028056 | Mar 2010 | WO |
WO 2010097632 | Sep 2010 | WO |
WO 2013067528 | May 2013 | WO |
WO 2014052477 | Apr 2014 | WO |
2014168631 | Oct 2014 | WO |
WO 2016044739 | Mar 2016 | WO |
WO 2016176496 | Nov 2016 | WO |
WO 2017100366 | Jun 2017 | WO |
Entry |
---|
International Search Report and Written Opinion dated Feb. 8, 2019 for International Application No. PCT/US2018/62292. |
Office Action dated May 5, 2017 in U.S. Appl. No. 15/141,655. |
Office Action dated Nov. 1, 2018 in U.S. Appl. No. 15/885,418. |
Final Office Action dated Feb. 25, 2019 in U.S. Appl. No. 15/885,418. |
Office Action dated Nov. 2, 2021 in U.S. Appl. No. 16/593,101. |
International Search Report and Written Opinion dated Aug. 19, 2016 in PCT/US2016/029865. |
Office Action dated Apr. 3, 2019 in Chinese Application No. 2016800391036. |
Office Action dated Jun. 28, 2019 in European Application No. 16722008.6-1132. |
Extended European Search Report dated Dec. 8, 2020 in European Application No. 20191843.0-1132. |
ISO/ASTM 52900:2015€ Standard Terminology for Additive Manufacturing—General Principles—Terminology, 2017. |
Office Action dated Mar. 5, 2020 in Japanese Application No. 2017-556733. |
Office Action dated Sep. 2, 2021 in Japanese Application No. 2020-156918. |
Notice of Decision to Grant a Patent dated Jul. 7, 2022 in Japanese Application No. 2020-156918. |
Office Action dated Sep. 2, 2021 in Japanese Application No. 2020-156917. |
Notice of Decision to Grant a Patent dated Jul. 7, 2022 in Japanese Application No. 2020-156917. |
Office Action dated May 2, 2018 in U.S. Appl. No. 15/334,053. |
Office Action dated Dec. 3, 2018 in U.S. Appl. No. 15/334,053. |
Office Action dated Sep. 15, 2022 in U.S. Appl. No. 16/700,632. |
Final Office Action dated Jun. 2, 2023 in U.S. Appl. No. 16/700,632. |
International Search Report and Written Opinion dated Jan. 18, 2018. |
“FDA Clears Camber Spine Technologies' 3D Printed SPIRA Open Matrix ALIF”, Orthopedic Design & Technology, Aug. 15, 2017. |
Supplemental Partial European Search Report dated May 15, 2020 in European Application No. 17866284. |
Office Action dated Sep. 3, 2020 in European Application No. 17866284. |
Office Action dated Mar. 23, 2022 in Chinese Application No. 2017800805197. |
Office Action dated Mar. 25, 2021 in Japanese Application No. 2019-543187. |
Office Action dated Aug. 5, 2021 in Japanese Application No. 2019-543187. |
Office Action dated Jan. 12, 2022 in Japanese Application No. 2019-543187. |
Preliminary Office Action dated Jan. 24, 2022 in Brazilian Application No. 112019008325-1. |
Office Action dated Feb. 16, 2023 in Japanese Application No. 2021-197842. |
Office Action dated Jul. 8, 2019 in U.S. Appl. No. 15/884,845. |
Final Office Action dated Oct. 24, 2019 in U.S. Appl. No. 15/884,845. |
International Search Report and Written Opinion dated Apr. 26, 2019 in PCT/US19/15946. |
Office Action dated Dec. 9, 2021 in Japanese Application No. 2020-540800. |
Office Action dated Apr. 27, 2023 in Japanese Application No. 2022-086976. |
Office Action dated Nov. 5, 2020 in Australian Application No. 2019214987. |
Office Action dated Oct. 15, 2021 in Australian Application No. 2019214987. |
Office Action dated Mar. 27, 2023 in Australian Application No. 2022200666. |
Office Action dated Oct. 25, 2018 in U.S. Appl. No. 15/791,279. |
Final Office Action dated Mar. 1, 2019 in U.S. Appl. No. 15/791,279. |
Office Action dated Mar. 1, 2022 in U.S. Appl. No. 16/659,011. |
Final Office Action dated Jun. 21, 2022 in U.S. Appl. No. 16/659,011. |
Office Action dated Feb. 27, 2023 in U.S. Appl. No. 16/659,011. |
Office Action dated Apr. 20, 2023 in JP Application No. 2022-124717. |
Number | Date | Country | |
---|---|---|---|
20210346171 A1 | Nov 2021 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15819930 | Nov 2017 | US |
Child | 17194999 | US |